Nevertheless, a whopping 72.9% said they did not want more education about their medication's risks and interactions with ...

The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...

With an accuracy of 86%, the biomarker panel has the potential to be clinically useful in diagnosis, management, and ...

NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...

Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan ...

Management holds 11th Annual ESG Investor Virtual Event on December 9 at 10 am. NVS ).webcasts.com/starthere.jsp?ei=1689776&tp_key=9312b9a422′ target= ‘_blank’; rel=’nofollow’>Webcast Link Discover ...

Novartis suffered a legal setback on Wednesday as the company failed to persuade a U.S. appeals court to halt MSN ...

The spinout startup has turned to Wefunder for its pre-seed raise while also landing support from a main ecosystem partner.

The global cancer supportive care drugs market is crucial in enhancing the quality of life and managing symptoms for cancer ...

CITRYLL RAISES EUR 85 MILLION SERIES B TO ADVANCE NOVEL NET-TARGETING THERAPY FOR IMMUNE-MEDIATED INFLAMMATORY DISORDERSFinancing co-led by ...

The letter Q can be distracting when talking about the heart, but this diversity is crucial and explains the title of the ...

High bad cholesterol is a risk factor for a common type of heart disease, yet approximately 40% of Americans living with high cholesterol don't know they have it and don't treat it1,2. Watch our Local ...